|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Spectrum of hepatitis B and renal involvement
Apurva S. Shah* andDeepak N. Amarapurkar
Version of Record online: 5 JUL 2017
DOI: 10.1111/liv.13498
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Liver International
Volume 38, Issue 1, pages 23–32, January 2018
Department of Gastroenterology, Bombay Hospital and Medical Research Institute, Mumbai, Maharashtra, India
Email: Apurva S. Shah ([email protected])
* Correspondence
Apurva S. Shah, Department of Gastroenterology, Bombay Hospital and Medical Research Institute, Mumbai, Maharashtra, India.
Email: [email protected]
Keywords:
hepatitis B vaccination;kidney transplant;membranous nephropathy;survival
Abstract
Renal involvement in hepatitis B occurs in various spectrums and its knowledge is important for clinicians in management of patients. The renal diseases most commonly associated with hepatitis B virus (HBV) infection include membranous nephropathy, membranoproliferative glomerulonephritis and Polyarteritis nodosa. The widespread use of hepatitis B vaccination has decreased the incidence of HBV-related renal diseases. The incidence of HBV infection in dialysis patients has significantly decreased over the past few decades because of screening of blood products for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody, implementation of infection control measures and hepatitis B vaccination. The definition of acute kidney injury has been recently modified in cirrhotic population, helping in prognosis and prediction of mortality. The most common etiologies of acute kidney injury in this cirrhotic population, which account for 80% to 90% of all cases, include volume depletion, acute tubular necrosis and hepatorenal syndrome. Treatment with oral nucleoside/tide analogues (NA) brought a new paradigm in the management of HBsAg positive glomerulonephritis, kidney transplant recipients and dialysis patients, resulting in effective viral suppression, reduced hepatic complications and improved patient survival, without compromising renal allograft outcome. NAs are cleared by the kidneys and therefore their dosage has to be adjusted in all patients with impaired renal function. This article reviews the recent knowledge of the pathogenesis and treatment of HBV-related glomerulonephritis and discusses the management of hepatitis B in patients on dialysis, kidney transplant recipients and cirrhotics, which is continuously evolving.
|
|
发表于 2017-12-23 07:59